Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Sees Large Growth in Short Interest

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 101,072 shares, a growth of 98.9% from the February 12th total of 50,818 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 81,504 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 81,504 shares, the short-interest ratio is presently 1.2 days. Currently, 0.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Northland Securities set a $15.00 price objective on Brainsway in a research report on Thursday, January 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. HC Wainwright reduced their price target on Brainsway from $30.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Brainsway Stock Performance

Shares of NASDAQ BWAY traded down $0.14 during midday trading on Thursday, reaching $13.64. 227,078 shares of the stock were exchanged, compared to its average volume of 216,917. The stock has a market capitalization of $534.76 million, a P/E ratio of 90.91 and a beta of 1.20. The company has a 50 day simple moving average of $11.96 and a 200 day simple moving average of $9.45. Brainsway has a twelve month low of $3.92 and a twelve month high of $14.65.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $14.55 million for the quarter, compared to analysts’ expectations of $14.02 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. On average, research analysts expect that Brainsway will post 0.08 earnings per share for the current year.

Key Headlines Impacting Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Q4 results beat expectations: Brainsway reported $0.14 EPS vs. $0.11 consensus and revenue of $14.55M vs. $14.02M, showing continued growth and a healthy net margin — this is likely supporting the stock despite other headwinds. Q4 & Full-Year Results
• Neutral Sentiment: Analyst action: HC Wainwright cut its price target sharply from $30 to $15 but kept a “Buy” rating — the lower target reduces upside expectations but the buy endorsement provides some support (the new PT implies modest upside from current levels). HC Wainwright Note
• Neutral Sentiment: Earnings call & transcripts posted: investors can review management commentary for detail on drivers and outlook (transcripts available). These documents add transparency and may influence sentiment once parsed. Earnings Call Transcript
• Negative Sentiment: Weak FY2026 revenue guidance: management provided revenue guidance of $51.0M–$52.0M, well below consensus (~$65M). This guidance gap is the primary negative catalyst weighing on the stock. Guidance Coverage
• Negative Sentiment: Analyst estimate trim: Northland Securities lowered its Q1 FY2026 EPS estimate from $0.04 to $0.03, signaling some near-term earnings pressure and lowering short-term expectations. Analyst Estimate Change
• Negative Sentiment: Rising short interest and prior jump in shorts: data showed a meaningful increase in short interest in February (101,072 shares, ~0.3% of shares), which can add selling pressure or volatility if sentiment worsens. Short Interest Data

Institutional Trading of Brainsway

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC acquired a new position in Brainsway in the fourth quarter valued at about $2,422,000. Y.D. More Investments Ltd raised its stake in shares of Brainsway by 559.8% in the 4th quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock valued at $2,187,000 after acquiring an additional 97,537 shares during the period. UBS Group AG lifted its holdings in shares of Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after acquiring an additional 60,877 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after acquiring an additional 20,706 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after purchasing an additional 16,354 shares during the period. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.